Miguel Colon Donate, MD
Hematology & Oncology · San Juan, PRNPI 1609262781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,402 of the $12,689 with a category attached, or 66.2%. 38 manufacturers reported payments, led by AstraZeneca at 39.5% of the total.
Across 392 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- E.r. Squibb & Sons, L.L.C.$883
- Eli Lilly Export S.A. Puerto Rico Branch$747
- Merck$726
- AbbVie$721
- PBG Puerto Rico LLC$593
- plus $4K from 32 others
Across 4 payments — averaging $5171.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$21K
What the payments were for
- Consulting fees$3,82430%
- Food & beverage$8,40266%
- Education$4634%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $5,006 |
| E.r. Squibb & Sons, L.L.C. | 36 | $883 |
| Eli Lilly Export S.A. Puerto Rico Branch | 34 | $747 |
| Merck | 34 | $726 |
| AbbVie | 32 | $721 |
| PBG Puerto Rico LLC | 28 | $593 |
| Novartis | 19 | $431 |
| Pfizer | 9 | $349 |
| Amgen | 17 | $336 |
| Genentech USA, Inc. | 16 | $310 |
| Taiho Oncology, Inc. | 12 | $280 |
| Bayer Puerto Rico Inc. | 10 | $233 |
| Johnson & Johnson | 10 | $221 |
| GSK | 5 | $181 |
| Astellas Pharma US Inc | 6 | $178 |
| Incyte Corporation | 5 | $166 |
| Sanofi | 6 | $133 |
| Seagen Inc. | 5 | $119 |
| Eisai Inc. | 6 | $111 |
| Caris MPI, Inc. | 4 | $97 |
| Gilead | 4 | $74 |
| Array Biopharma Inc | 5 | $72 |
| Tempus AI, Inc | 3 | $71 |
| Ipsen Biopharmaceuticals, Inc | 3 | $70 |
| Puma Biotechnology, Inc. | 4 | $68 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Tolmar, Inc. | 3 | $62 |
| Exelixis Inc. | 3 | $56 |
| Pfizer Pharmaceuticals LLC | 3 | $55 |
| Pharmaessentia USA Corporation | 2 | $52 |
| Beone Medicines USA, Inc. | 2 | $52 |
| Novo Nordisk | 2 | $37 |
| Boehringer Ingelheim | 1 | $25 |
| Global Blood Therapeutics, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Telix Pharmaceuticals | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,689 in reported general payments places this provider in the 55th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 13 | $318,233 |
| Anastrozole | 201 | $3,892 |
| Exemestane | 15 | $2,741 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $560 |
| Tamoxifen Citrate | 18 | $448 |
| Ondansetron Hcl | 37 | $402 |
| Famotidine | 43 | $282 |
| Dexamethasone | 12 | $263 |
| Pantoprazole Sodium | 12 | $164 |
| Omeprazole | 20 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $111 | $318,23313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Edgardo Santiago-GuzmanSan Juan$79K
- Adelba Torres-LopezSan Juan$73K
- Karla Feliciano SalvaSan Juan$44K
- Luis Delgado MateuSan Juan$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.